Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 999326 in Japanese Subjects With High-grade, BCG Unresponsive NMIBC
NCT05704244Phase 3Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Nov 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 3 trial of nadofaragene firadenovec in non-muscle-invasive bladder cancer (NMIBC), sponsored by Ferring Pharmaceuticals. Started Dec 2022; status: active, not recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05704244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704244.